Corcept Therapeutics Incorporated (NASDAQ:CORT) Stake Raised by Natixis Advisors LLC

Natixis Advisors LLC raised its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 14.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,123 shares of the biotechnology company’s stock after acquiring an additional 3,979 shares during the quarter. Natixis Advisors LLC’s holdings in Corcept Therapeutics were worth $1,619,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Corcept Therapeutics by 40.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,223,781 shares of the biotechnology company’s stock worth $56,637,000 after purchasing an additional 352,947 shares during the period. Braun Stacey Associates Inc. purchased a new position in shares of Corcept Therapeutics during the 4th quarter valued at $14,935,000. FMR LLC increased its stake in shares of Corcept Therapeutics by 24.6% in the third quarter. FMR LLC now owns 1,363,922 shares of the biotechnology company’s stock worth $63,122,000 after acquiring an additional 269,074 shares during the last quarter. Synergy Asset Management LLC raised its holdings in shares of Corcept Therapeutics by 131.3% during the fourth quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock worth $22,369,000 after acquiring an additional 262,503 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Corcept Therapeutics during the fourth quarter valued at $12,084,000. Institutional investors and hedge funds own 93.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on CORT shares. StockNews.com downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. Canaccord Genuity Group raised their price objective on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, January 30th. Piper Sandler boosted their target price on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $115.00 price target on shares of Corcept Therapeutics in a report on Thursday, February 27th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Corcept Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.75.

Insider Buying and Selling

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $68.08, for a total value of $149,776.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $50.39, for a total value of $1,007,800.00. Following the sale, the insider now directly owns 85,318 shares in the company, valued at approximately $4,299,174.02. This trade represents a 18.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 45,627 shares of company stock valued at $2,557,674. Insiders own 20.50% of the company’s stock.

Corcept Therapeutics Trading Up 1.4 %

Shares of CORT stock opened at $59.47 on Tuesday. Corcept Therapeutics Incorporated has a 12 month low of $20.84 and a 12 month high of $75.00. The company has a market cap of $6.27 billion, a PE ratio of 47.20 and a beta of 0.61. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $61.66 and its two-hundred day moving average is $54.13.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm had revenue of $181.89 million during the quarter, compared to the consensus estimate of $200.12 million. Equities analysts predict that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.